Literature DB >> 9364276

Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group.

T Grodzicki1, A Palmer, C J Bulpitt.   

Abstract

Hypertension has been shown to be closely associated with metabolic disorders such as diabetes mellitus and gout. The aim of this study was to establish the incidence of both these diseases in hypertensive patients and their age-matched controls and to assess the risk associated with diuretic treatment. The results refer to the data base of 2295 hypertensive and 2280 controls from the General Practice Hypertension Study Group who were screened for hypertension. The rescreened hypertensive subjects (n = 1190) and their controls (n = 938) were followed for an average of 8 years. The diagnosis of diabetes and gout was made by their general practitioners. After 8 years of follow-up, diabetes mellitus was diagnosed in 5.0% of hypertensive and 1.5% normotensive subjects. The diagnosis of gout was made in 3.1% and 0.9%, respectively. Moreover, diabetes mellitus occurred more frequently in both hypertensive men and women, with diuretic treatment and without (respectively, men given diuretic: relative risk (RR) = 2.74, 95% confidence interval (CI): 0.99, 7.5; and men not given diuretic: RR = 2.25, 95% CI: 1.0, 5.3: women RR = 4.03 95% CI: 1.5, 10.8, and RR = 3.47, 95% CI: 1.4, 8.9) in comparison with their age-matched controls. For gout the excess was confirmed in hypertensive men with and without diuretic treatment (RR = 6.25 (95% CI: 2.4, 16.7) vs 3.93 (95% CI: 1.6, 9.7)).

Entities:  

Mesh:

Year:  1997        PMID: 9364276     DOI: 10.1038/sj.jhh.1000496

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; E Pascual; T Bardin; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

Review 2.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

3.  Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; H R Schumacher; K G Saag
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

Review 4.  Racial and gender disparities among patients with gout.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2013-02       Impact factor: 4.592

5.  Common questions and answers in the management of hypertension: Am I more likely to develop diabetes if I have high blood pressure?

Authors:  Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

6.  Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies.

Authors:  Peter L Evans; James A Prior; John Belcher; Christian D Mallen; Charles A Hay; Edward Roddy
Journal:  Arthritis Res Ther       Date:  2018-07-05       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.